Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)
David Robert Spigel, Michael McCleod, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2019
Cited by 185 works. doi:10.1016/j.jtho.2019.05.010
Authors
- David Robert Spigel
- Michael McCleod
- Robert M. Jotte
- Lawrence H. Einhorn
- Leora Horn
- David Michael Waterhouse
- Ben Creelan
- Sunil Babu
- Natasha B. Leighl
- Jason Claud Chandler
- George P. Keogh
- Glenwood D. Goss
- Davey B. Daniel
- Edward B. Garon
- Lee Steven Schwartzberg
- Rohini Sen
- Beata Korytowsky
- Ang Li
- Nivedita Aanur
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
- Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population
- Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research
- Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
- Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study